Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Pharmaxis Ltd ( (AU:SNT) ).
Syntara Limited has initiated the AZALOX clinical trial, a Phase 1b/2 study, to evaluate the safety and efficacy of amsulostat (SNT-5505) in combination with 5-Azacitidine for treating high-risk Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML). The trial, supported by German Cancer Aid and conducted across nine centers under Heidelberg University sponsorship, aims to determine the optimal dosage and assess the treatment’s potential to improve patient outcomes, potentially reducing the need for blood transfusions and the risk of progression to acute myeloid leukemia.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.27 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company focused on developing innovative treatments for blood cancers. The company is involved in creating therapies that target high-risk Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML), expanding its research to address significant unmet medical needs in these areas.
Average Trading Volume: 10,419,319
Technical Sentiment Signal: Sell
Current Market Cap: A$79.67M
For an in-depth examination of SNT stock, go to TipRanks’ Overview page.